Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Mesylate in Recurrent Meningioma
NCT00045734Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2003
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in meningioma and hemangiopericytoma (HPC), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 6 months. Started Feb 2003; status: completed.
02
Drugs
03
Conditions
meningiomahemangiopericytoma (HPC)
Beyond the preview
Go deeper on NCT00045734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045734.